Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine in Patients With Tourette's Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* High impulsive patients, aged 10-35 years old, diagnosed for Tourette's syndrome as defined by the DSM-IV, never treated by Atomoxetine~* The use of effective contraception or abstinence for subjects of reproductive age~* Written informed consent~Exclusion Criteria:~* Patients with mental retardation, psychotic disorders as schizophrenia, autism spectrum disorders, chronic tics which do not respond to Tourette's syndrome criteria.~* Actual severe depression~* Allergy to one of the constituents~* Severe cardiovascular or cerebrovascular diseases, Pheochromocytoma, uncontrolled hyperthyroidism, closed angle glaucoma~* IMAO treatment discontinued less than 2 months or contra-indicated associated treatment

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- patients with Tourette's syndrome (Type: EXPERIMENTAL): Atomoxetine in Patients With Tourette's Syndrome

Based on this trial design, predict the completion outcome and termination type (if applicable).